TORONTO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Lophos Holdings (The “Company”) is pleased to provide an update on its wholly owned subsidiary Lophos Pharmaceuticals (“Lophos”). Lophos is a psychedelic research company primarily focused on novel therapeutic treatments derived from Peyote (Lophophora williamsii).
Lophos has made significant strides in launching operations at their recently acquired 10,000 square foot facility in Ontario. Progress at the facility is ahead of schedule thanks to the recent submission of their Controlled Drugs and Substances Dealer’s License application. The approval of this license will allow Lophos to cultivate peyote and other mescaline producing cacti, as well as allowing their in-house laboratory to perform research and analysis on extracted psychedelic alkaloids.
“The submission of the Dealer’s License application is a significant step forward in our ability to supply patients of the SAP program and I couldn’t be happier with the progress the Lophos team has made to date,” said Claire Stawnyczy, CEO of Lophos Pharmaceuticals. “We look forward to Health Canada’s inspection of the facility and will continue providing updates on our progress.”
About Lophos Pharmaceuticals
Lophos is a biosciences company that specializes in Peyote research, cultivation, preservation, and drug development. We develop novel therapies and natural health treatments that aim to restore and improve the quality of life for patients. Through advanced cultivation and harvesting techniques, Lophos Pharmaceuticals will provide our partners with medical grade inputs and our patients with access to safe and effective mescaline-based therapeutics.
Contact
Claire Stawnyczy, CEO
info@lophos.com
Forward Looking Statements
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Company’s psychedelics program. Forward-looking information is based on reasonable assumptions that have been made by the Company at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein.
